Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000267 · ClinicalTrials.gov registry record · Phase 2
Risperidone Treatment in Dually-Diagnosed Individuals - 2
A Phase 2 study of Cocaine-Related Disorders, sponsored by National Institute on Drug Abuse (NIDA).
- Completed
- Registry status
- Phase 2
- Development phase
- 1
- Study location
NCT00000267 is a Phase 2 study of Cocaine-Related Disorders that has completed, run by National Institute on Drug Abuse (NIDA). The trial reports 1 study location across 1 state.
The verdict
NCT00000267, a Phase 2 study of Cocaine-Related Disorders, has completed, sponsored by National Institute on Drug Abuse (NIDA).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the safety and efficacy of risperidone for cocaine dependence in individuals with schizophrenia/schizoaffective illness.
Conditions Studied
Interventions
- DRUG Risperidone
Study Locations (1)
New York
- New York State Psychiatric Institute - New York
Trial Details
| Field | Value |
|---|---|
| Est. Completion | 2001-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00000267
The ClinicalTrials.gov registry entry for NCT00000267 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is National Institute on Drug Abuse (NIDA), which has 335 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cocaine-Related Disorders appearing as the primary indexed condition, and to 1 intervention - of which Risperidone is the first listed.
NCT00000267 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT00000267 about?
NCT00000267 is a clinical study titled "Risperidone Treatment in Dually-Diagnosed Individuals - 2". The purpose of this study is to evaluate the safety and efficacy of risperidone for cocaine dependence in individuals with schizophrenia/schizoaffective illness.
What is the current status of trial NCT00000267?
This trial is currently completed. It is a Phase 2 study. Estimated completion is 2001-12.
What conditions does trial NCT00000267 study?
This clinical trial studies the following conditions: Cocaine-Related Disorders.
What interventions are being tested in trial NCT00000267?
The interventions under investigation include: Risperidone (DRUG).
Who is sponsoring clinical trial NCT00000267?
This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00000267 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cocaine-Related Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Developing Adaptive Interventions for Cocaine Cessation and Relapse Prevention
COMPLETED · Phase 2
-
Atomoxetine for Treating Cocaine Abuse in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
COMPLETED · Phase 2
-
Pharmacological Modulation of Cocaine Effects - 1
COMPLETED · Phase 2
-
Gepirone vs Placebo in Treatment of Cocaine Dependence - 3
COMPLETED · Phase 2
-
Combination of Disulfiram Plus Naltrexone to Treat Both Cocaine- and Alcohol-dependent Individuals - 1
COMPLETED · Phase 2
-
Evaluation of Benztropine for Cocaine Craving - 2
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.